Monte Rosa Therapeutics Inc (NASDAQ:GLUE) has a beta value of 1.38 and has seen 0.85 million shares traded in the last trading session. The company, currently valued at $471.22M, closed the last trade at $7.67 per share which meant it lost -$0.01 on the day or -0.13% during that session. The GLUE stock price is -61.67% off its 52-week high price of $12.40 and 58.15% above the 52-week low of $3.21. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.35 million shares traded. The 3-month trading volume is 2.58 million shares.
The consensus among analysts is that Monte Rosa Therapeutics Inc (GLUE) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.2.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) trade information
Sporting -0.13% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the GLUE stock price touched $7.67 or saw a rise of 22.05%. Year-to-date, Monte Rosa Therapeutics Inc shares have moved 35.75%, while the 5-day performance has seen it change -18.75%. Over the past 30 days, the shares of Monte Rosa Therapeutics Inc (NASDAQ:GLUE) have changed -0.90%. Short interest in the company has seen 11.05 million shares shorted with days to cover at 8.2.
Monte Rosa Therapeutics Inc (GLUE) estimates and forecasts
Figures show that Monte Rosa Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 116.67% over the past 6 months, with this year growth rate of 43.35%, compared to 17.20% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
7 analysts offering their estimates for the company have set an average revenue estimate of 51.19M for the current quarter. 4 have an estimated revenue figure of 6.1M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -96.71% over the past 5 years.
GLUE Dividends
Monte Rosa Therapeutics Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s Major holders
Insiders own 0.70% of the company shares, while shares held by institutions stand at 90.60% with a share float percentage of 91.25%. Investors are also buoyed by the number of investors in a company, with Monte Rosa Therapeutics Inc having a total of 121.0 institutions that hold shares in the company. The top two institutional holders are NEA MANAGEMENT COMPANY, LLC with over 7.69 million shares worth more than $28.77 million. As of 2024-06-30, NEA MANAGEMENT COMPANY, LLC held 12.7872% of shares outstanding.
The other major institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, with the holding of over 5.98 million shares as of 2024-06-30. The firm’s total holdings are worth over $22.36 million and represent 9.9368% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Price (T.Rowe) New Horizons Fund and Vanguard Total Stock Market Index Fund . As of Sep 30, 2024 , the former fund manager holds about 5.54% shares in the company for having 3.41 shares of worth $26.13 million while later fund manager owns 1.35 shares of worth $10.36 million as of Sep 30, 2024 , which makes it owner of about 2.20% of company’s outstanding stock.
